Full Breakdown
Health Secretary Robert F. Kennedy Jr. Distances Himself from FDA's Rejection of Replimune's Cancer Drug
4/23/2026, 1:27:40 AM
Overview of the FDA's Decision
On April 10, 2026, the U.S. Food and Drug Administration (FDA) declined to approve Replimune's drug, RP1, intended for advanced skin cancer treatment. The FDA's rejection was based on the company's reliance on a single-arm study without a control group, which the agency deemed insufficient to demonstrate the drug's effectiveness. Following this decision, Replimune's stock plummeted nearly 70%, although it saw a 15% increase on April 22 after Health Secretary Robert F. Kennedy Jr. addressed the issue during a Senate hearing.
Health Secretary's Testimony
During the Senate hearing, Kennedy asserted that he had no involvement in the FDA's decision-making process, attributing the decision to FDA Commissioner Dr. Marty Makary. He stated, “This decision comes out of FDA, and we trust the process there,” and claimed that every panel reviewing the drug had unanimously voted against it. However, this assertion has been challenged by several oncologists.
Disputed Claims and Expert Opinions
Critics, including cancer specialists, have contested Kennedy's statements regarding the drug's trial. They highlighted that an initial panel had approved the drug before being overruled by Dr. Vinay Prasad, the head of biologics at the FDA. Furthermore, Kennedy's claim that trial participants received chemotherapy was incorrect; they were treated with a different form of immunotherapy. Dr. Anna Pavlick, a melanoma researcher involved in the trial, expressed confidence in the drug's potential, stating, “Honestly, there was no doubt in our minds whatsoever... that this was going to be approved as a wonderful alternative for our patients because they have no options.”
Official Statements and Responses
Andrew Nixon, a spokesperson for the Department of Health and Human Services (HHS), emphasized that FDA career scientists unanimously determined that the evidence provided by Replimune did not meet the required standards for regulatory approval. This statement reflects the FDA's commitment to maintaining rigorous standards for drug approval, despite the backlash from some medical professionals.
Criticism and Opposition
The rejection of RP1 has sparked significant criticism, particularly regarding the FDA's leadership and decision-making processes. An opinion piece in The Wall Street Journal criticized Kennedy for his remarks, suggesting that denying patients access to potentially life-saving medication for unclear reasons indicates a need for leadership changes within the FDA. The piece also highlighted the frustrations of oncologists who believe the drug could offer vital treatment options for patients with limited alternatives.
Conflicting Reports and Gaps
There are discrepancies regarding the FDA's decision-making process and the effectiveness of Replimune's drug. While Kennedy claims unanimous opposition from review panels, oncologists argue that initial support existed before the decision was overturned. Additionally, the nature of the trial's treatment regimen has been misrepresented, leading to confusion about the drug's potential efficacy.
What's Next
The ongoing debate surrounding Replimune's drug and the FDA's regulatory practices may prompt further investigations and discussions about drug approval processes in the U.S. As stakeholders continue to voice their opinions, the future of RP1 remains uncertain, with potential implications for both the company and patients seeking new treatment options.
